Brief: Akari Therapeutics Says Nomacopan Receives Orphan Drug Designation From European Commission
27/07/2023 14:59
July 27 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS - GRANTED NOMACOPAN ORPHAN DRUG
DESIGNATION
FROM EUROPEAN COMMISSION FOR TREATMENT IN HEMATOPOIETIC STEM
CELL TRANSPLANTATION
* AKARI THERAPEUTICS - MOVING FORWARD INTO PHASE 3 TRIAL OF
NOMACOPAN IN ADULT HSCT-TMA WITH ENROLLMENT EXPECTED TO BEGIN IN
2024
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))